Browse Studies — Arctuva

Phase 3

Evaluation of Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74 PET/CT Imaging)

Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see thi…

Allogeneic Stem Cell TransplantationLung Allograft TransplantationInterstitial Lung Disease+3 more

Estimated

~$10 – $5,625

National Heart, Lung, and Blood Institute (NHLBI)NCT07613099

Phase 2

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Anti-CD14 Treatment With a Recombinant Chimeric Monoclonal Antibody (IC14) in Hospitalized Patients With Acute Respiratory Distress Syndrome

Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be foll…

Acute Respiratory Distress SyndromeAdult Respiratory Distress SyndromeAcute Lung Injury+1 more

Estimated

~$10 – $7,500

Implicit BioscienceNCT06513949

RETURN: Recovery of Physical Function After Critical Illness In Older Adults

The proposed study is a prospective, observational study assessing the recovery of muscle and physical function in patients surviving critical illness (n =150)…

SepsisAcute Lung Injury(ALI)

Estimated

~$10 – $750

University of KentuckyNCT07225257

Phase 2

A Randomized Trial of CCR5 Inhibition as a Complement to Lung Transplant Induction Immunosuppression

Lung transplant recipient survival lags other solid organ recipients, with the main early cause of death being primary graft dysfunction (PGD). PGD occurs in u…

Primary Graft DysfunctionLung TransplantationAcute Lung Injury(ALI)+1 more

Estimated

~$10 – $5,625

University of California, San FranciscoNCT06853223